Prolonged Postpartum Proteinuria after Early Preeclampsia

American Journal of Kidney Diseases

Volumn 43, Issue 1, 2004, Pages 186-191

  Durham, John H C ^b   Desnick, Robert J ^b   Imbriano, Louis ^b   Wasserstein, Melissa ^b   D'Agati, Vivette D ^b   Markowitz, Glen S ^a  

^a College of Physicians and Surgeons ^*  (United States)

^b NONE

Author keywords

Fabry disease; Postpartum proteinuria; Preeclampsia

Indexed keywords

ALPHA GALACTOSIDASE; CALCIUM; CARBON DIOXIDE; CREATININE; MAGNESIUM; MAGNESIUM SULFATE; METHYLDOPA; PHOSPHATE; SODIUM; URIC ACID;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE ASSOCIATION; DISEASE SEVERITY; EDEMA; FABRY DISEASE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; KIDNEY BIOPSY; MISSENSE MUTATION; MUTATIONAL ANALYSIS; PREECLAMPSIA; PROTEINURIA; PUERPERIUM; UREA NITROGEN BLOOD LEVEL; URINALYSIS;

EID: 0346728940     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2003.08.048     Document Type: Article

References (29)

1. Dekker GA, de Vries JI, Doelitzsch PM, et al: Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynecol 173:1042-1048, 1995
2. Moore MP, Redman CW: Case-control study of severe pre-eclampsia of early onset. Br Med J (Clin Res Ed) 287:580-583, 1983
3. Sibai BM, Mercer B, Sarinoglu C: Severe preeclampsia in the second trimester: Recurrence risk and long-term prognosis. Am J Obstet Gynecol 165:1408-1412, 1991
4. Sibai BM, el-Nazer A, Gonzalez-Ruiz A: Severe preeclampsia-eclampsia in young primigravid women: Subsequent pregnancy outcome and remote prognosis. Am J Obstet Gynecol 155:1011-1016, 1986
5. Sibai BM: Management and counseling of patients with preeclampsia remote from term. Clin Obstet Gynecol 35:426-436, 1992
6. Ihle BU, Long P, Oats J: Early onset pre-eclampsia: Recognition of underlying renal disease. Br Med J (Clin Res Ed) 294:79-81, 1987
7. Chua S, Redman CW: Prognosis for pre-eclampsia complicated by 5 g or more of proteinuria in 24 hours. Eur J Obstet Gynecol Reprod Biol 43:9-12, 1992
8. Colley J, Miller D, Huntt M, Wallace H: The renal lesion in angiokeratoma corporis diffusum. Brit Med J 1:1266-1268, 1958
9. Meroni M, Sessa A, Battini G, Tazzari S, Torri Tarelli L: Kidney involvement in Anderson-Fabry disease. Contrib Nephrol 122:178-184, 1997
10. Desnick RJ, Ioannou YA, Eng CM: a-Galactosidase A deficiency: Fabry disease, in Scriver CR, Beaudet AL, Sly WS, Valle D, Kinzler KE, Vogelstein B (eds): The Metabolic and Molecular Bases of Inherited Disease (ed 8). New York, NY, McGraw-Hill, 2001, p 3733-3774
11. MacDermot KD, Holmes A, Miners AH: Anderson-Fabry disease: Clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 38:769-775, 2001
12. Willard HF: The sex chromosome and X chromosome inactivation, in Scriver CR, Beaudet AL, Sly WS, Valle D, Kinzler KE, Vogelstein B (eds): The Metabolic and Molecular Bases of Inherited Disease (ed 8). New York, NY, McGraw-Hill, 2001, p 1191-1212
13. Shabbeer J, Yasuda M, Luca E, Desnick RJ: Fabry disease: 45 novel mutations in the a-galactosidase A gene causing the classical phenotype. Mol Genet Metab 76:23-30, 2002
14. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L: Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med 276:1163-1167, 1967
15. Branton MH, Schiffmann R, Sabnis SG, et al: Natural history of Fabry renal disease: Influence of a-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 81:122-138, 2002
16. Thadhani R, Wolf M, West ML, et al: Patients with Fabry disease on dialysis in the United States. Kidney Int 61:249-255, 2002
17. Whybra C, Kampmann C, Willers I, et al: Anderson-Fabry disease: Clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis 24:715-724, 2001
18. Hopkin RJ, Bissler J, Grabowski GA: Comparative evaluation of a-galactosidase A infusions for treatment of Fabry disease. Genet Med 5:144-153, 2003
19. Bird TD, Lagunoff D: Neurological manifestations of Fabry disease in female carriers. Ann Neurol 4:537-540, 1978
20. Desnick RJ, Simmons RL, Allen KY, et al: Correction of enzymatic deficiencies by renal transplantation: Fabry's disease. Surgery 72:203-211, 1972
21. Rietra P, Brouwer-Kelder E, de Groot W, Tager J: The use of biochemical parameters for the detection of carriers of Fabry's disease. J Mol Med 1: 237-255, 1976
22. Avila JL, Convit J, Velazquez-Avila G: Fabry's disease: Normal a-galactosidase activity and urinary-sediment glycosphingolipid levels in two obligate heterozygotes. Br J Dermatol 89:149-157, 1973
23. Levade T, Giordano F, Maret A, Marguery MC, Bazex J, Salvayre R: Different phenotypic expression of Fabry disease in female monozygotic twins. J Inherit Metab Dis 14:105-106, 1991
24. Gubler MC, Lenoir G, Grunfeld JP, Ulmann A, Droz D, Habib R: Early renal changes in hemizygous and heterozygous patients with Fabry's disease. Kidney Int 13:223-235, 1978
25. Chen HC, Tsai JH, Lai YH, Guh JY: Renal changes in heterozygous Fabry's disease-A family study. Am J Kidney Dis 15:180-183, 1990
26. Eng CM, Banikazemi M, Gordon R, et al: A phase 1/2 clinical trial of enzyme replacement in Fabry disease: Pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 68:711-722, 2001
27. Eng CM, Guffon N, Wilcox WR, et al: Safety and efficacy of recombinant human a-galactosidase A replacement therapy in Fabry's disease. N Engl J Med 345:9-16, 2001
28. Thurberg BL, Rennke H, Colvin RB, et al: Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 62:1933-1946, 2002
29. De Schoenmakere G, Chauveau D, Grunfeld JP: Enzyme replacement therapy in Anderson-Fabry's disease: Beneficial clinical effect on vital organ function. Nephrol Dial Transplant 18:33-35, 2003